Ubs Asset Management Americas Inc Dyne Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 127,550 shares of DYN stock, worth $4.16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,550
Previous 31,281
307.76%
Holding current value
$4.16 Million
Previous $888,000
406.87%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$261 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$256 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$241 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$208 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$197 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.69B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...